Advertisement

NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Matthew Ong: What are your thoughts about the NEJM paper on atezolizumab in triple-negative breast cancer?

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
Advertisement
Advertisement